EYPT - EyePoint Pharma slumps on offering of $100M common shares

EyePoint Pharmaceuticals (NASDAQ:EYPT) has launched an underwritten public offering of $100M of shares of its common stock. Actual size and other terms of the offering are yet to be determined. Underwriters may be granted a 30-day option to purchase up to an additional $15M of common shares. Net proceeds from the offering will be used to advance EYP-1901 into and through Phase 2 clinical trials for wet AMD, DR, and RVO, as well as support earlier stage pipeline development initiatives, and for general corporate purposes. Yesterday, EyePoint Pharma reported positive EYP-1901 data for treatment of wet AMD EYPT -7.33% AH.

For further details see:

EyePoint Pharma slumps on offering of $100M common shares